Drug Profile
Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical/Vanderbilt University
Alternative Names: BMP type-I receptor antagonist - La Jolla Pharmaceutical/Vanderbilt UniversityLatest Information Update: 16 Nov 2015
Price :
*
At a glance
- Originator Vanderbilt University Medical Center
- Class Small molecules
- Mechanism of Action Bone morphogenetic protein receptor type I antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrodysplasia ossificans progressiva; Musculoskeletal disorders
Most Recent Events
- 18 Aug 2015 Early research in Fibrodysplasia ossificans progressiva in USA (unspecified route)
- 18 Aug 2015 La Jolla receives Orphan Drug status for two bone morphogenetic protein type-1 receptor antagonists for Fibrodysplasia ossificans progressiva in USA
- 18 Aug 2015 Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical/Vanderbilt University receives Orphan Drug status for Fibrodysplasia ossificans progressiva in USA